An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Aurore,Perrot

第一单位： Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.

作者： Aurore,Perrot ^[1] ; Sosana,Delimpasi ^[2] ; Emmanouil,Spanoudakis ^[3] ; Ulf,Frølund ^[4] ; Angelo,Belotti ^[5] ; Albert,Oriol ^[6] ; Philippe,Moreau ^[7] ; Ian,McFadden ^[8] ; Qing,Xia ^[8] ; Mukta,Arora ^[8] ; Meletios Athanasios,Dimopoulos ^[9]

作者单位： Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France. ^[1] General Hospital Evangelismos, Athens, Greece. ^[2] University General Hospital of Evros-Alexandroupolis District, Alexandroupolis, Greece. ^[3] Department of Haematology, Zealand University Hospital, Roskilde, Denmark. ^[4] Hematology Division, ASST Spedali Civili Brescia, Brescia, Italy. ^[5] Hematology Department, Insitut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain. ^[6] Hematology Department, University Hospital, Nantes, France. ^[7] Amgen Inc., Thousand Oaks, CA, USA. ^[8] Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece. ^[9]

关键词 Carfilzomib EudraCT 2019-001169-34 NCT04191616 lenalidomide refractory pomalidomide relapsed/refractory multiple myeloma triple-class refractory